Safety and Effectiveness of Regdanvimab for COVID-19 Treatment: A Phase 4 Post-marketing Surveillance Study Conducted in South Korea

INTRODUCTION: Regdanvimab, a neutralising monoclonal antibody (mAb) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), received approval for the treatment of coronavirus disease 2019 (COVID-19) in South Korea in 2021. The Ministry of Food and Drug Safety in South Korea mandate tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Ji Yeon, Bu, Seon Hee, Song, EunHyang, Cho, Seongcheol, Yu, Sungbong, Kim, Jungok, Kym, Sungmin, Seo, Kwang Won, Kwon, Ki Tae, Kim, Jin Yong, Kim, Sunghyun, Ahn, Keumyoung, Jung, Nahyun, Lee, Yeonmi, Jung, Yoobin, Hwang, Chankyoung, Park, Sang Won
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600078/
https://www.ncbi.nlm.nih.gov/pubmed/37833467
http://dx.doi.org/10.1007/s40121-023-00859-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600078/
https://www.ncbi.nlm.nih.gov/pubmed/37833467
http://dx.doi.org/10.1007/s40121-023-00859-1

Ejemplares similares